BioNTech Stock Dips On FDA Concerns Over Cancer Drug Trial: Retail Response Mixed

Barchart · 10/18 11:44
Morgan Stanley noted that this is “an incremental negative” for the stock. However, it maintains its ‘Overweight’ rating on the stock.